Eilmeldung - 500 Beiträge pro Seite

[LLDave]

10 Januar 2005 12:00 PM Zeitzone Berlin

Sanofi-aventis Reaffirms Commitment to Alliance with Regeneron Pharmaceuticals

BIOWIRE2K

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Jan. 10, 2005--Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)


-- Partners Approve Broad-Based Cancer Development Program for the VEGF Trap

-- Regeneron to Receive $25 Million Clinical Development Milestone Payment Plus Additional $25 Million Payment

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that, following a review of the Vascular Endothelial Growth Factor (VEGF) Trap program, they have reaffirmed their commitment to develop the VEGF Trap in oncology in collaboration with Regeneron Pharmaceuticals Inc. (Nasdaq: REGN). The companies will evaluate the VEGF Trap in a variety of cancer types, both in single-agent studies and in combination with chemotherapy. Sanofi-aventis also announced that Regeneron has earned a $25 million clinical development milestone payment.

"This is an exciting time for us as we continue to gather evidence on the potential of the VEGF Trap to block the formation of blood vessels that fuel the growth of cancerous tumors. All of us at Regeneron are looking forward to working with sanofi-aventis to accelerate the development of the VEGF Trap," noted Leonard S. Schleifer, M.D., Ph.D., Regeneron`s President and Chief Executive Officer. "Sanofi-aventis is clearly committed to discovery, development, and commercialization of innovative products. Its expertise in oncology, driven by its commitment to the VEGF Trap, can provide a great resource for us in moving the program forward."

Marc Cluzel, M.D., Ph.D., Vice President, International Development, Sciences & Medical Affairs of sanofi-aventis added "This is an important partnership for sanofi-aventis and we continue to believe that the blockage of VEGF is one of the most innovative approaches to targeted cancer therapy."

In addition, the companies have agreed that the exclusive right to develop and commercialize the VEGF Trap for eye diseases through local delivery systems reverts today to Regeneron. The collaboration will not currently pursue systemic delivery for eye disease.

In connection with this agreement, sanofi-aventis will make a one-time, final payment to Regeneron of $25 million of which 50% is repayable to sanofi-aventis following commercialization of the VEGF Trap.

About Regeneron

Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer and eye diseases, rheumatoid arthritis and other inflammatory conditions, asthma, and obesity and has preclinical programs in other diseases and disorders. Regeneron corporate headquarters are in Tarrytown, NY. For more information, please visit www.regn.com.

About Sanofi-aventis

Sanofi-aventis is the world`s 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, vaccines. Sanofi-aventis is listed in Paris (EURONEXT:SAN) and in New York (NYSE:SNY).

Forward-looking Statements

For Regeneron:

This news release discusses historical information and includes forward-looking statements about Regeneron and its products, programs, finances, and business, all of which involve a number of risks and uncertainties, such as risks associated with preclinical and clinical development of drugs and biologics, determinations by regulatory and administrative governmental authorities, competitive factors, technological developments, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any collaboration agreement to be canceled or to terminate without any product success, and other material risks. A more complete description of these risks can be found in Regeneron`s filings with the United States Securities and Exchange Commission, including its Form 10-K(A) for the year ended December 31, 2003 and Form 10-Q for the quarter ended September 30, 2004. Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law.

For sanofi-aventis:

This press release may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. These statements include financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expect," "anticipates," "believes," "intends," "estimates" and similar expressions. Although management of sanofi-aventis and aventis believe that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis and Aventis, including those listed under "Forward-Looking Statements" and "Risk Factors" in their respective annual reports on Form 20-F for the year ended December 31, 2003. Other than as required by applicable law, neither sanofi-aventis nor Aventis undertakes any obligation to update or revise any forward-looking information or statements.

Additional information about Regeneron and recent news releases are available on Regeneron`s Worldwide Web Home Page at www.regeneron.com

Kontakte


Investors:
Regeneron Pharmaceuticals, Inc.
Vice President, Investor Relations
Charles Poole, 914-345-7640
[e-mail]
or
Media:
Media Relations
Lauren Tortorete, 212-845-5609
[e-mail]

[Berta Roker]

mk 350 mio euro, was soll da ein lausiger 25 mio dollar deal?

[LLDave]

warten wir mal auf die Amis
ich persönlich rechne mit einem SK von 10$

du kannst es ja mal hiermit probieren:

07 Januar 2005 08:00 PM Zeitzone Berlin

Multispectral Solutions(MSSI.OB) Receives FCC Certification for Ultra Low Power, UWB Active RFID Tag

GERMANTOWN, Md.--(BUSINESS WIRE)--Jan. 7, 2005--The FCC has issued a Grant of Equipment Authorization for Multispectral Solutions` ultra low power, ultra wideband (UWB) active Radio Frequency Identification (RFID) tag. The tag is the fourth in a series of FCC-certified UWB products from the company, and is compatible with the company`s PAL650(TM) Precision Asset Location System(TM) product line.


The tag measures approximately 1 x 1 x 0.8 inches including battery, and has a range of approximately 650 feet line-of-sight and better than 150 feet in partially obstructed environments. With its unique design, the tag draws only 6 microamps at 3.0V while transmitting at a once per second update rate. With a small cell battery, tag life expectancy is in excess of 4 years, over 2 orders of magnitude longer than other active RFID tags operating at the same blink rate. When operating with the PAL650 system, the tag can be used for either RFID at extended ranges through obstructions, or for precision tracking to better than 4 inch accuracy and resolution.

"Active RFID solutions had been placed on a back burner to passive designs due to their poor power efficiencies, poor transmission ranges, miserable performance in multipath and large physical size," stated Dr. Robert Fontana, MSSI president and CEO. "Our PAL650 RFID and tracking product line has demonstrated that viable and cost-effective active solutions are here today which can satisfy a wide range of industrial and consumer applications."

About Multispectral Solutions, Inc.

Multispectral Solutions, Inc. (MSSI), established in 1989 in Germantown, MD, is a pioneer and established industry leader in the development of ultra wideband (UWB) systems for communications, radar and precision positioning applications. The company`s PAL650 Precision Asset Location system is the world`s first FCC-certified, UWB-based, active RFID and tracking system for personnel and asset management.

[scrabbler]

die zweite meldung ist auch nicht ohne, leider verkauft keiner bei uns!
ich glaube auch, dass die meldung bei den amis gut ankommt, vor allem, da die kooperation nicht mit irgendeinem unternehmen sondern mit sanofi-aventis über die bühne geht....leider lässt der umsatz bei uns zu wünschen übrig1
schwer welche zu bekommen und auch zu verkaufen, es sei denn, die aktie explodiert drüben, mal sehen!
beobachte erstmal

[LLDave]

da kaufen die ersten in Berlin (noch zu 6,32:eek

[scrabbler]

scheisse, zu spät reagiert.

[LLDave]

vielleicht hast Du ja Glück und die Amis kaufen erstmal nicht, dann könnten Deine 300 Stück doch noch bedient werden
vorbörslich noch nichts passiert, geht immer erst kurz vor zwei los

[scrabbler]

8,30$(8,25 im Ask zu 11,10 im Bid)

[scrabbler]

8,59 (+5,40%)

[LLDave]

sogar 8,66 (über 6%)
bringt DIR aber gar nichts, Dein Order wurde ja nicht augeführt

[scrabbler]

doch, zu 6,33!!
go go Rege

[scrabbler]

Tageshoch: 6,69$

[scrabbler]

sorry, 8,69$

[scrabbler]

bei 8,50$ bildet sich ein Boden

[scrabbler]

SK: 8,50$
Gute Voraussetzungen für Heute